The dizziness issue has been evident since 2015, the AD phase 2A. This is the first time the company pointed out it can be additionally mitigated with bedtime administration of the drug.
On the discrepancies, I suspect we'll be getting explanations from the company quickly, maybe even a new results deck. With a one-day turnaround, a couple mistakes will happen (Though simple double-checking can catch them.)